Multi-Drug Resistance in Chronic Lymphocytic Leukemia

References

• Curt G. A., Clendeninn N. J., Chabner B. A. Drug resistance in cancer. Cancer Treatment Reports 1984; 68: 87–99
   PubMedGoogle Scholar
• Goldie J. H., Coldman A. J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Riordan J. R., Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacology and Therapeutics 1985; 28: 51–75
   PubMed Web of Science ®Google Scholar
• Pastan I., Gottesman M. Multiple-drug resistance in human cancer. New England Journal of Medicine 1987; 316: 1388–1393
   PubMed Web of Science ®Google Scholar
• Hochhauser D., Harris A. L. Mechanisms of multi-drug resistance. Haematological Oncology, A. Newland, A. Burnett, A. Keating, J. Armitage. Cambridge University Press, United Kingdom 1991; Vol. 1: 29–48
   Google Scholar
• Beck W. T. Modulators of p-glycoprotein associated multidrug resistance. Drug Resistance, R. F. Ozols. Kluwer Academic Publishers, Norwell, MA 1991
   Google Scholar
• Dalton W. S., Grogan T. M. Does P-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it. Journal of the National Cancer Institute 1991; 83: 80–81
   PubMed Web of Science ®Google Scholar
• Dohner H., Fischer K., Bentz M., Hansen K., Benner A., Cabot G., Diehl D., Schlenk R., Coy J., Stilgenbauer S., Volkmann M., Galle P. R., Poustka A., Hunstein W., Lichter P. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589
   PubMed Web of Science ®Google Scholar
• Benchimol S., Ling V. P-glycoprotein and tumor progression. Journal of the. National Cancer Institute 1994; 86: 814–816
   PubMed Web of Science ®Google Scholar
• Braverman A. S. Chemotherapeutic failure: Resistance or insensitivity. Annals of Internal Medicine 1993; 118: 630–632
   PubMed Web of Science ®Google Scholar
• O'Brien S., Del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307–318
   PubMed Web of Science ®Google Scholar
• Faguet G. B. Chronic lymphocytic leukemia: An updated review. Journal of Clinical Oncology 1994; 12: 1974–1990
   PubMed Web of Science ®Google Scholar
• Marie J. P. P-glycoprotein in adult hematologic malignancies. Hematology/Oncology Clinics of North America 1995; 9: 239–249
   PubMed Web of Science ®Google Scholar
• Ford J. M. Modulators of multidrug resistance: Preclinical studies. Hematology/Oncology Clinics of North America 1995; 9: 337–361
   PubMed Web of Science ®Google Scholar
• Slater L. M., Sweet P., Stupecky M., Gupta S. Cyclosporine A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. Journal of Clinical Investigation 1986; 77: 1405–1408
   PubMed Web of Science ®Google Scholar
• Osieka R., Seeber S., Pannenbacker R., Soll D., Glatte P., Schmidt C. G. Enhancement of etoposide-induced cytotoxicity by cyclosporine A. Cancer Chemotherapy and Pharmacology 1986; 18: 198–202
   PubMed Web of Science ®Google Scholar
• Nooter K., Sonneveld P., Oostrum R., Herweijer H., Hagenbeek T., Valerio D. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporine-A. International Journal of Cancer 1990; 45: 263–268
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Dalton W. S., Grogan T. M., Plezia P., Lehnert M., Roe D. J., Miller T. P. Multidrug-resistant myeloma. Laboratory and clinical effects of chemosensitizers. Blood 1991; 78: 44–50
   PubMed Web of Science ®Google Scholar
• Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of mdrl and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. Journal of the National Cancer Institute 1990; 82: 1133–1140
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Nooter K. Reversal of drug-resistance by cyclosporine-A in a patient with acute myelocytic leukaemia. British Journal of Haematology 1990; 75: 208–211
   PubMed Web of Science ®Google Scholar
• Twentyman P. R., Wright K. A., Wallace H. M. Cyclosporine-A and non-immunosuppressive analogs inhibit growth of human lung cancer cells in vitro. Proceedings of the American Association of Clinical Research 1989; 30: 483
   Google Scholar
• Jonsson B., Nilsson K., Nygren P., Larsson R. SDZ PSC-833, a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs 1992; 3: 641–646
   PubMed Web of Science ®Google Scholar
• Jaffrezou J. P., Sikic B. I., Laurent G. Cyclosporine-A and cyclosporine SDZ PSC-833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Blood 1994; 83: 482–489
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Marie J. P., Lokhorst H. M., Nooter K., Schoester M. Clinical modulation of multidrug resistance in VAD-refractory multiple myeloma: studies with cyclosporine and SDZ PSC-833. Anticancer Drugs 1994; 5: 72
   Google Scholar
• Erlichman C., Moore M., Thiessen J., De Angelis C., Goodman P., Manzo J. A phase I trial of doxorubicin (DOX) and PSC-833, a modulator of multidrug resistance (MDR). Anticancer Drugs 1994; 5: 42
   Google Scholar
• Giaccone G., Linn S. C., Catimel G., Dumortier A., Foy M., Vermorken J. B., Koier I., Welink J., Van der Vijgh W. J. F., Eeltink C., Laburte C., Pinedo H. M. SDZ PSC-833 in combination with doxorubicin: A phase I and pharmacologic study in solid tumors. Anticancer Drugs 1994; 5: 42
   Google Scholar
• Fisher G. A., Halsey J., Hausdorff J., Lum B. L., Brophy N. A., Collins H., Nix D., Sikic B. I. A phase I study of paclitaxel (taxolR) (T) in combination with SDZ PSC-833, a potent modulator of multidrug resistance (MDR). Anticancer Drugs 1994; 5: 43
   PubMedGoogle Scholar
• Erlichman C., Moore M. J., De Angelis C., Goodman P., Manzo J. The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC-833, in patients with advanced cancer. Anticancer Drugs 1994; 5: 44
   Google Scholar
• Lum B. L., Fisher G. A., Hausdorff J., Halsey J., Collins H., Brophy N. A., Ehsan M. N., Sikic B. I. The effect of oral SDZ PSC-833 on the pharmacokinetics (PK) of etoposide (E) during a phase I trial to modulate multidrug resistance. Anticancer Drugs 1994; 5: 44
   Google Scholar
• Twentyman P. R., Bleehen N. M. Resistance modification by PSC-833, a novel nonimmunosuppressive Cyclosporine-A. European Journal of Cancer 1991; 27: 1639–1642
   PubMed Web of Science ®Google Scholar
• Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC-833. Cancer Research 1991; 51: 4226–4233
   PubMed Web of Science ®Google Scholar
• Schrek R. Chronic lymphocytic leukemic patients, resistant to chemotherapy. Medical Hypotheses 1988; 26: 277–288
   Web of Science ®Google Scholar
• Cumber P. M., Jacobs A., Hoy T., Fisher J., Whittaker J. A., Tsuruo T., Padua R. A. Expression of the multiple drug resistance gene (MDR-1) and epitope masking in chronic lymphatic leukaemia. British Journal of Haematology 1990; 76: 226–230
   PubMed Web of Science ®Google Scholar
• Shustik C., Groulx N., Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). British Journal of Haematology 1991; 79: 50–56
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Nooter K., Burghouts J. T. M., Herweijer H., Adriaansen H. J., Van Dongen J. J. High expression of the MDR3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496–1500
   PubMed Web of Science ®Google Scholar
• El Rouby S., Thomas A., Costin D., Rosenberg C. R., Potmesil M., Silber R., Newcomb E. W. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Holmes J. A., Jacobs A., Carter G., Whittaker J. A., Bentley D. P., Padua R. A. Is the MDR1 gene relevant in chronic lymphocytic leukemia. Leukemia 1990; 4: 216–218
   PubMed Web of Science ®Google Scholar
• Michieli M., Raspadori D., Damiani D., Geromin A., Gallizia C., Michelutti A., Fanin R., Fasola G., Russo D., Tazzari P., Piled S., Mallardi F., Baccarani M. The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. British Journal of Haematology 1991; 77: 460–465
   PubMed Web of Science ®Google Scholar
• Ludescher C., Hilbe W., Eisterer W., Preuss E., Huber C., Gotwald M., Hofmann J., Thaler J. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. Journal of the National Cancer Institute 1993; 85: 1751–1758
   PubMed Web of Science ®Google Scholar
• Sparrow R. L., Hall F. J., Siregar H., Van der Weyden M. B. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leukemia Research 1993; 17: 941–947
   PubMed Web of Science ®Google Scholar
• Beck W. T., Grogan T. M., Willman C. L., Cordon-Cardo C., Parham D. M., Kuttesch J. F., Andreeff M., Bates S. E., Berard C. W., Boyett J. M., Brophy N. A., Broxterman H. J., Chan H. S., Dalton W. S., Dietel M., Fojo A. T., Gascoyne R. D., Head D., Houghton P. J., Scrivastava D. K., Lehnert M., Leith C. P., Paietta E., Pavelic Z. P., Weinstein R. Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Research 1996; 56: 3010–3020
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Bennett J. M., Grever M., Kay N., Keating M. J., O'Brien S., Rai K. R. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Bruno N. A., Slate D. L. Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug-resistant cells. Journal of the National Cancer Institute 1990; 82: 419–424
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Grogan T., Dalton W., Rybaki J., Spier C., Meltzer P., Richter L., Gleason M., Pindur J., Cline A., Scheper R., Tsuruo T., Salmon S. Optimization of immunocytochemical P-glycoprotein assessment in multidrug resistant plasma cell myeloma using three antibodies. Laboratory Investigation 1990; 63: 815–824
   PubMed Web of Science ®Google Scholar
• Broxterman H. J., Sonneveld P., Feller N., Ossenkoppele G. J., Wahrer D. C., Eekman C. A., Schoester M., Lankelma J., Pinedo H. M., Lowenberg B., Schuurhuis G. J. Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for p-glycoprotein expression and activity. Blood 1996; 87: 4809–4816
   PubMed Web of Science ®Google Scholar
• Leith C. P., Chen I.-M., Kopecky Appelbaum K. J., Head F. R. D. R., Godwin J. E., Weick J. K., Willman C. L. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR−/efflux+ and MDR+/efflux− cases. Blood 1995; 86: 2329–2342
   PubMed Web of Science ®Google Scholar
• Abbaszadegan M. R., Futscher B. W., Klimecki W. T., List A., Dalton W. S. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Research 1994; 54: 4676–4679
   PubMed Web of Science ®Google Scholar
• Gruber A., Larsson R., Nygren P., Bjorkholm M., Peterson C. A non-p-glycoprotein-mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells. Leukemia 1994; 8: 985–989
   PubMed Web of Science ®Google Scholar
• Brophy N. A., Marie J. P., Rojas V. A., Warnke R. A., McFall P. J., Smith S. D., Sikic B. I. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: A critical evaluation by four techniques. Leukemia 1994; 8: 327–335
   PubMed Web of Science ®Google Scholar
• Herzog C. E., Trepel J. B., Mickley L. A., Bates S. E., Fojo A. T. Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. Journal of the National Cancer Institute 1992; 84: 711–716
   PubMed Web of Science ®Google Scholar
• Rao V. V., Anthony D. C., Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Research 1994; 54: 1536–1541
   PubMed Web of Science ®Google Scholar
• Georges E., Bradley G., Gariepy J., Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 152–156
   PubMed Web of Science ®Google Scholar
• Chaudhary P. M., Roninson I. B. Expression and activity of p-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94
   PubMed Web of Science ®Google Scholar
• Drach D., Zhao S., Drach J., Mahadevia R., Gattringer C., Huber H., Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729–2734
   PubMed Web of Science ®Google Scholar
• Marie J.-P., Brophy N. A., Ehsan M. N., Aihara Y., Mohamed N. A., Cornbleet J., Chao N. J., Sikic B. I. Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. British Journal of Hematology 1992; 81: 145–152
   PubMed Web of Science ®Google Scholar
• Marie J.-P., Legrand O., Perrot J.-Y., Chevillard S., Huet S., Robert J. Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations. Seminars in Hematology 1997; 34: 63–71
   PubMed Web of Science ®Google Scholar
• Hart S. M., Ganeshaguru K., Prentice H. G., Hoffbrand A. V., Mehta A. B. Multidrug resistance (MDR1) expression and function is decreased in advanced stage chronic lymphocytic leukaemia (CLL). Blood 1996; 88: 363a
   Google Scholar